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Skeletal muscle is a major storage site for glycogen and a focus for understanding
insulin resistance and type-2-diabetes. New evidence indicates that overactivation of the
peripheral endocannabinoid system (ECS) in skeletal muscle diminishes insulin sensitivity.
Specific n-6 and n-3 polyunsaturated fatty acids (PUFA) are precursors for the biosynthesis
of ligands that bind to and activate the cannabinoid receptors. The function of the ECS
and action of PUFA in skeletal muscle glucose uptake was investigated in proliferating
and differentiated C2C12 myoblasts treated with either 25μM of arachidonate (AA) or
docosahexaenoate (DHA), 25μM of EC [anandamide (AEA), 2-arachidonoylglycerol (2-AG),
docosahexaenoylethanolamide (DHEA)], 1μM of CB1 antagonist NESS0327, and CB2
inverse agonist AM630. Compared to the BSA vehicle control cell cultures in both
proliferating and differentiated myoblasts those treated with DHEA, the EC derived from
the n-3 PUFA DHA, had higher 24 h glucose uptake, while AEA and 2-AG, the EC derived
from the n-6 PUFA AA, had lower basal glucose uptake. Adenylyl cyclase mRNA was
higher in myoblasts treated with DHA in both proliferating and differentiated states while
those treated with AEA or 2-AG were lower compared to the control cell cultures.
Western blot and qPCR analysis showed higher expression of the cannabinoid receptors
in differentiated myoblasts treated with DHA while the opposite was observed with AA.
These findings indicate a compensatory effect of DHA and DHEA compared to AA-derived
ligands on the ECS and associated ECS gene expression and higher glucose uptake in
myoblasts.
Keywords: endocannabinoid system, C2C12 myoblasts, cannabinoid receptors, glucose uptake, gene expression,
DHEA, polyunsaturated fatty acids
INTRODUCTION
Skeletal muscle serves as a major target organ for glucose removal
from circulation and the relevancy of this tissue is bolstered by
the disease states of insulin resistance and diabetes. Under eug-
lycemic conditions in healthy subjects, approximately 75% of
glucose removal is mediated by non-insulin stimulated glucose
uptake primarily by the brain and to a lesser extent in other
tissues such as skeletal muscle (Baron et al., 1988). However,
under hyperglycemic conditions, glucose uptake mediated via
non-insulin stimulated glucose uptake increases considerably
(Capaldo et al., 1986). Moreover, the importance of basal glucose
Abbreviations: 2-AG, 2-arachidonoylglycerol; 2-NBDG, 2-deoxy-2-[(7-nitro-
2,1,3-benzoxadiazol-4-yl) amino]-D-glucose; AA, arachidonic acid; AEA,
N-arachidonoylethanolamine; anandamide; ALA, α-linolenic acid; AMPK,
AMP-activated protein kinase; BSA, bovine serum albumin; CB1, cannabi-
noid receptor 1; CB2, cannabinoid receptor 2; DAGLα, diacylglycerol lipase-α;
DAGLβ, diacylglycerol lipase-β; DHA, docosahexaenoic acid; DHEA, docosahex-
aenoyl ethanolamide; DM, differentiation media; EC, endocannabinoid; ECS,
endocannabinoid system; EPA, eicosapentaenoic acid; EPEA, eicosapentaenoyl
ethanolamide; FAAH, fatty acid amide hydrolase; FACS, fluorescence activated
cell sorting; FAME, fatty acid methyl ester; GM, growth media; IL, interleukin;
IRS-1, insulin receptor substrate-1; LA, linoleic acid; MAPK, mitogen-activated
protein kinase; NAPE-PLD, N-acyl phosphatidylethanolamine phospholipase;
PUFA, polyunsaturated fatty acid; qPCR, quantitative polymerase chain reaction;
TNF-α, tumor necrosis factor-α.
uptake is apparent during insulin resistance and diabetes when
close to 80% of glucose uptake is achieved postprandially (Best
et al., 1996).
In recent years, researchers have identified a physiologic mech-
anism that regulates the balance of macronutrient metabolism.
The endocannabinoid system (ECS) is a complex network encom-
passing various physiological systems in the body that is com-
prised of the G-protein-coupled receptors, CB1 and CB2, their
lipid-derived endogenous ligands termed endocannabinoids, and
the enzymes that are involved in the biosynthesis/degradation of
the endocannabinoids. While the ECS has been shown to influ-
ence several physiological activities, such as hunger, pain modu-
lation, mood, and inflammation, the primary function appears to
impact energy homeostasis, as activation of the ECS appears to
shift energy balance toward energy storage (De Petrocellis et al.,
1999; Soderstrom et al., 2004; Valenti et al., 2005; Piazza et al.,
2007).
Previous findings confirm the role of the ECS in food intake
and energy homeostasis. Reduced food intake was reported in
mice (Despres et al., 2005) by pharmacologically antagonizing
CB1 as well as in CB1 knockout mice (Pi-Sunyer et al., 2006).
The interest in targeting this specific cannabinoid receptor is sup-
ported by several key findings. Importantly, antagonism of CB1
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reduced food intake and body weight (Cota et al., 2003; Ravinet
Trillou et al., 2003). However, the reduced food intake did not
account for the total reduction in body weight, suggesting an ulte-
rior means of energy expenditure. Furthermore, in both obese
subjects and in leptin deficient mice, reduced glucose uptake and
fatty acid oxidation were observed to be reversed by antagoniz-
ing CB1 (Liu et al., 2005; Cavuoto et al., 2007). Along with this,
blood concentrations of the two chiefly studied endocannabi-
noids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG)
both derived from arachidonic acid (AA), are elevated in obese
compared to lean individuals (Bluher et al., 2006; Matias et al.,
2006).
In support of CB1 exerting a role on energy balance, evi-
dence from several studies in animal models as well as in humans
revealed that in conditions of obesity and hyperglycemia the ECS
is in an overactivated state (Engeli et al., 2005; Bluher et al., 2006;
Matias et al., 2006). This phenomenon is referred to as ECS tone,
which is the collective actions of ligands, receptors, and enzymes
of endocannabinoid synthesis and degradation. In other words,
the ECS is overactivated in the state of obesity. Thus in the over-
activated state a dysregulated ECS observed in both the obese
and an insulin resistive state contributes to greater lipid accu-
mulation and insulin resistance in muscle. Targeting the ECS to
improve signaling for maintaining healthy muscle glucose sen-
sitivity and reduce excessive lipid accumulation is an attractive
application. Moreover findings that the ECS plays an active role
in macronutrient metabolism we propose that directing endoge-
nous agonist actions on the ECS to improve glucose homeostasis
has implications for diabetes and obesity.
Recognizing that dietary sources of fatty acids andmore specif-
ically the polyunsaturated fatty acids (PUFA) can alter tissue
composition of membrane phospholipids, dietary manipulation
permits indirect control of the ECS on cellular functions. It is well
known that the amount and type of dietary n-6 and n-3 PUFA
changes the PUFA composition of membrane phospholipids in
various tissues including muscle and bone compartments (Brown
et al., 1991; Watkins et al., 2003; Hutchins-Wiese et al., 2012).
Additionally, studies onmouse adipocytes demonstrated that cul-
tures incubated with AA or docosahexaenoic acid (DHA) for 72 h
elevated levels of these PUFA in phospholipids compared to the
vehicle controls (Matias et al., 2008). Furthermore, AA treatment
in the adipocyte cultures led to an increase of 2-AG concentra-
tions while DHA treatment significantly decreased both AEA and
2-AG concentrations compared to the vehicle control.
Various studies on feeding rodents different dietary PUFA
resulted in alterations in the levels of endocannabinoids of brain
(Watanabe et al., 2003), adipose (Batetta et al., 2009), and liver
(Artmann et al., 2008; Batetta et al., 2009). Mice fed a high
fat diet supplemented with krill oil for 8 weeks were found to
have reduced levels of AA-derived endocannabinoids in vari-
ous peripheral tissue, including gastrocnemius (Piscitelli et al.,
2011). Changes were reported in ECS genes of muscle when
different dietary PUFA were fed to mice. For example, in our
laboratory, analysis of quadriceps muscle from male ND4 Swiss
Webster mice fed either a control diet (AIN-93G with safflower
oil) or a high n-3 PUFA diet (EPA+DHA 17.6 g/kg) for 26 days
revealed changes in several ECS genes (Hutchins-Wiese et al.,
2012). We reported that the mRNA for AEA synthesis enzyme,
N-acyl phosphatidylethanolamine phospholipase (NAPE-PLD),
and 2-AG synthesis enzyme, diacylglycerol lipase (DAGL)α and
DAGLβ, were higher in muscle of mice fed the n-3 PUFA diet
compared to the controls. Furthermore, in this study the mRNA
expression of CB1 and CB2 were both higher in muscle of mice
fed the high n-3 PUFA diet. Collectively, these findings strongly
suggest that dietary n-3 PUFA treatment can alter mRNA expres-
sion of key ECS genes to influence ECS signaling.
Since cellular membranes participate in numerous physiologi-
cal and biochemical processes, changing the PUFA composition
of cell membranes through diet can alter signaling and recep-
tor functions associated with the ECS. Based on these findings
that ECS gene expression changed upon exposure to different
amounts and families of PUFA, the ECS is likely to adapt and
change accordingly to these nutrients that serve as EC precur-
sors. Therefore, an investigation exploring the adaptations from
dietary PUFA enrichment on the skeletal muscle ECS is warranted
as this signaling system is actively involved in energy homeostasis.
To investigate the role of the ECS on basal glucose uptake, our
overall research hypothesis was that dietary long chain n-3 PUFA,
DHA, and EPA, enrichment of C2C12 myoblasts restores endo-
cannabinoid tone (action of ligands, receptors, and enzymes of
the ECS synthesis and degradation) and signaling of this system
to improve glucose homeostasis with potential applications to
reduce obesity and diabetes. Since ECS receptor activation likely
plays a role in impacting glucose uptake, the investigation also
evaluated the consequences of PUFA treatment with cannabi-
noid receptor agonists and antagonists. The specific aim of this
research was to describe the effects of PUFA enrichment on endo-
cannabinoid gene expression and agonist/antagonist actions on
glucose homeostasis in the myoblast cell line C2C12. Herein,
C2C12 myoblast cell cultures were enriched with 25μM lev-
els of PUFA and the mRNA (qPCR) and protein expression
(Western blot) of endocannabinoid enzymes and cannabinoid
receptors were quantified. The expression of these enzymes and
receptors were studied in myoblast cell cultures in both the
proliferative and differentiation committed states. Additionally,
insulin signaling/glucose uptake was measured as a consequent
outcome.
MATERIALS AND METHODS
CELL CULTURES AND TREATMENTS
C2C12 cells were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA) and routinely cultured
in growth media (GM) consisting of Dulbecco’s Modified Eagles
Medium (DMEM; Thermo Fisher Scientific,Waltham,MA, USA)
supplemented in 10% fetal bovine serum (FBS, Thermo Fisher
Scientific, Waltham, MA, USA), and 1% antibiotic solution or in
differentiation media (DM), consisting of DMEM with 2% horse
serum (Thermo Fisher Scientific, Waltham, MA, USA) in place
of FBS. Cultures were maintained in vented 75 cm2 tissue cul-
ture flasks (Becton Dickinson and Company, Franklin Lakes, NJ,
USA) at a density of 1 × 106 cells per flask as determined by auto-
mated TC-10 cell counter (Bio-Rad laboratories, Inc., Hercules,
CA, USA). Seeded at this density, cultures became 80–85% con-
fluent after 72 h, at which time the cells were passed onto new
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flasks containing fresh GM. C2C12 cell cultures in all experiments
were from passages 5–9.
Proliferating and differentiated cells were used to model skele-
tal muscle, such as within an ex vivo model or whole organ-
ism. Skeletal muscle found in mammals contains a mix of both
proliferating and differentiating myoblasts (during active regen-
eration from injury, in addition to routine organ maintenance
and homeostasis). Differentiated C2C12 were chosen to mimic
mature myofibers. Myogenin and MyoD1, markers of differenti-
ation, were used to verify that myoblasts had committed toward
differentiation.
CHEMICALS AND REAGENTS
The treatment media contained PUFA AA, EPA, and DHA all
from Nu-Chek-Prep, Inc. (Elysian, MN, USA) and endocannabi-
noids (AEA and 2-AG from Abcam, PLC., Cambridge, MA, USA)
that were dissolved in 100% ethanol at a final concentration
of 100mg/mL, flushed with N2 and stored in glass amber vials
at −20◦C until needed. The PUFA containing media were pre-
pared by adding fatty acid stock aliquots to either serum free
GM containing endotoxin/fatty acid free BSA (Sigma Chemical
Company, Saint Louis, MO, USA) that was used at a con-
centration dependent of PUFA concentration (2:1, PUFA:BSA).
Working concentrations of the PUFA stock solutions were diluted
as appropriate to achieve the necessary final concentrations. Cell
cultures were treated for 24 h in 37◦C at 5%CO2. 24 h prior to cell
collection then treated with varying physiologic concentrations of
AA, EPA, DHA, AEA, or 2-AG at 25μM while 5, 10, and 25μM
for the glucose uptake experiments. Additionally, NESS0327, a
CB1 antagonist, or AM630, a CB2 inverse agonist were used to
pretreat cells at concentrations of 1, 2, or 5μM.
FATTY ACID METHYL ESTERS ANALYSIS OF C2C12 CELL CULTURES
Fatty acid methyl esters (FAME) analysis was performed to mea-
sure fatty acid composition in C2C12 myoblast cultures, which
were washed with calcium/magnesium-free phosphate buffered
saline (PBS; 137mM NaCl, 2.7mM KCl, 9.9mM Na2HPO4,
1.8mM KH2PO4; Thermo Fisher Scientific, Waltham, MA, USA)
and removed by scraping with a Teflon scraper. Cells were
sonicated and extracted for lipids with chloroform/methanol
(2:1, vol/vol) (Thermo Fisher Scientific, Waltham, MA, USA).
Extracted lipids were treated with 0.5N NaOH in methanol,
and FAME prepared by esterification using boron trifluoride
(BF3) in methanol (10% w/w, Supelco Inc., Bellefonte, PA, USA).
The FAME were concentrated in isooctane (HPLC grade, Fisher
Scientific, Pittsburg, PA, USA) and analyzed by gas chromatogra-
phy (GC) (HP 7890A series, autosampler 7693, GC ChemStation
Rev.B.04.03, Agilent Technologies, Palo Alto, CA, USA) with a
DB-225 column (30m, 0.25mm i.d., 0.15mm film thickness,
Agilent Technologies, Palo Alto, CA, USA) equipped with a flame
ionization detector (Li et al., 2010). Sample peaks were identi-
fied by comparison to authentic FAME standards (Nu-Chek-Prep
Inc., Elysian, MN, USA). Sample injection volume was 3μL and
split ratio 10:1. Results for FAME analysis were obtained by weight
percentage reports based on the response values for authentic
standards of known concentrations to determine weight per-
centages values. This approach facilitates lipid and subsequent
FAME recovery to minimize losses in peak responses at lower
concentrations of components.
QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (qPCR)
Analysis of mRNA expression of genes of interest was mea-
sured to understand changes in ECS and glucose-related genes
after PUFA or endocannabinoid treatment. C2C12 cells were
cultured in 75 cm2 flasks until 85–90% confluent, followed by
treatment with fatty acid or endocannabinoid. Afterwards, cells
were washed twice with cold PBS, followed by RNA extraction
with TRIzol (Invitrogen Corp., Carlsbad, CA, USA) reagent. RNA
samples were then treated with DNase I (Ambion, Carlsbad,
CA, USA) to remove any DNA contamination. Total RNA
(1μg) was reverse transcribed to cDNA in a reaction mix-
ture using RNA transcriptase superscript III (Invitrogen Corp.,
Carlsbad, CA, USA). Briefly, 9μL of the following were com-
bined for each sample: 4μL 5X VILO reaction mix containing
random hexamers and dNTPs, 2μL 10X Superscript enzyme
mix® (BioRad Laboratories, Hercules, CA, USA) containing
RNA inhibitors, and 3μL of DEPC treated water for a total
volume of 20μL. Samples were heated as specified for super-
script RT: 25◦C for 10min, 42◦C for 60min, and 85◦C for
5min. Synthesized cDNA product was then used for quanti-
tative RT-PCR. A master mix for RT-PCR was prepared with
SsoFast EvaGreen® Supermix (BioRad Laboratories, Hercules,
CA, USA). Briefly, 10μL SsoFast EvaGreen® was mixed with
6μL DEPC treated water, 1μL of 10μM forward primer, and
1μL of 10μM reverse primer. A total of 18μL of master mix
was added to wells of unskirted 96-well plates with 2μL of
cDNA. All samples were analyzed in triplicate. Fluorescence
emission was detected and cycle threshold (CT) values were cal-
culated in the linear range automatically. Relative CT amounts
were calculated from the standard curve for each gene, which
were normalized to the reference gene, GAPDH, afterwards. The
primers sequences used in this work are shown in Table 1.CT
values for each sample were determined by calculating the dif-
ference between the CT value of the target gene and the CT
value of the reference gene, GAPDH. The normalized level of
expression of the target gene in each sample was calculated
using the formula 2−CT. Values were expressed as fold of the
control.
WESTERN BLOT ANALYSIS
Protein expressions of genes were analyzed by collecting whole
cell lysates after incubation with PUFA treatments. Cells were
washed twice with cold PBS followed by scraping to dislodge from
surface and transferred to 1.5mL microfuge tubes to be lysated
using a lysis buffer (100mM Tris-HCl + 0.1% Triton X-100, pH
7.5). Lysates were then centrifuged at 12,000 g for 5min at 4◦C,
after in which the supernatant was collected and stored at −80◦C.
Proteins were then separated by polyacrylamide gel (gradi-
ent 4–15%) electrophoresis then transferred to a PVDF mem-
brane, to be followed by antibody incubation against the protein
of interest (α-mouse-CB1, α-mouse-CB2, α-rabbit-GLUT4, α-
rabbit-Insulin-R, Abcam, PLC., Cambridge, MA, USA). Protein
expression was detected using Westpico horseradish peroxidase
chemiluminescence and imaged using a Chemidoc XRS+ system
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Table 1 | Primer sequences used for quantitative polymerase chain reaction (qPCR).
Gene Forward Reverse Accession
GAPDH TGTGATGGGTGTGAACCACGAGAA GAGCCCTTCCACAATGCCAAAGTT GU214026.1
CB1 TCACACCTCAGAAGATGGCAAGGT AGCAGATGATCAACACCACCAGGA AY522554.1
CB2 TGAAGATCGGCAGTGTGACCATGA AATGCTGAGAGGACCCACATGACA U21681.1
NAPE-PLD TGGCATTGTGCATGAAAGCCCTAC AGTGGGCATGGTGTAGTTGTCAGT AB112350.1
FAAH TGGCATTGTGCATGAAAGCCCTAC AGTGGGCATGGTGTAGTTGTCAGT NM_010173.4
DAGL-α CGACCACCAAGTGCAACCATTGAA AACTCGGCGAATTCTAGCACCTGA BC148308.2
DAGL-β TGTGTGTCAGCATGAGAGGAACCA GTGGCGATGATGCCAATGACAACT BC016105.1
Akt-1 GTAGCCATTGTGAAGGAG TCTTGAGGAGGAAGTAGC AF124142.1
Insulin-R TCCTGGAAATCGTCAACCTGCTCA ACGATCCAACGGGACATTCTCCAT J05149.1
IRS-1 GGCACATCTCCTACCATT CATCATCTCTGTATATTCCTCAAT NM_010570.4
GLUT4 TCGTGGCCATATTTGGCTTTGTGG TAAGGACCCATAGCATCCGCAACA AB008453.1
GLUT1 CATCGCCCTGGCCCTGCAGGAGC GGCACCCCCCTGCCGGAAGCCGGA D10229.1
Adiponectin AATGACAGGAGCTGAAGGGC AGGTGAAGAGAACGGCCTTG NM_009605.4
Myogenin CGTGGGCATGTAAGGTGTGTAAGA CATTCACTTTCTTGAGCCTGCGCT M95800.1
MyoD1 TGAGCAAAGTGAATGAGGCCTTCG AGAGCCTGCAGACCTTCGATGTA M18779.1
IL-6 ATCCAGTTGCCTTCTTGGGACTGA TAAGCCTCCGACTTGTGAAGTGGT M20572.1
TNF-α AGCCGATGGGTTGTACCTTGTCTA TGAGATAGCAAATCGGCTGACGGT D84199.2
MCP-1 TGAGCCATGGGAACAAGGAAGTCT TGTGCTGGTCTGTGATAGGCACAT BC055070.1
AMPK-α2 TCCTGAAGACCCCTCCTACG GAGTGGTTCTCAGCTGTGCT NM_178143.2
Adenylyl cyclase GAAAGTGCGAACCCAGAGGA ACTTGCGGACGTGTTCAGAT AF458089.1
p42/p44 (MAPK) AGCCACACGTTGGTACAGAG CCAGAGCTTTGGAGTCAGCA X58712.1
p38 (MAPK) GGCTGATGAGGAGATGACCG ATGGGAGGCAGAGACTGGAT AF135185.1
JNK (MAPK) AGTGGGTTGCATCATGGGAG CTGCATCTGAAGGCTGGTCT NM_016700.4
and Image Lab software (BioRad Laboratories, Hercules, CA,
USA) (Tsang et al., 1989).
FLOW CYTOMETRY
In addition to Western blot analysis, FACS flow cytometry was
also used to measure expression of cannabinoid receptors. C2C12
cultures were washed twice with cold PBS followed by scraping
to dislodge from surface and transferred to 1.5mL microfuge
tubes to be incubated with primary antibodies (α-goat-CB1 and
α-rabbit-CB2, Abcam, PLC., Cambridge, MA, USA) diluted in
FACS buffer (1:250) for 1 h in 4◦C. Afterwards, cells were cen-
trifuged at 500 g for 5min (4◦C) and washed 3 times. Following
washing, secondary antibodies (goat α-rabbit 488 and donkey
α-goat FITC; Thermo Scientific, Abcam, PLC, Cambridge, MA,
USA) were diluted in FACS buffer (1:500) for 1 h in 4◦C in the
dark. Cells were then centrifuged at 500 g for 5min (4◦C) and
washed 3 times. Cells were resuspended in 1mL of FACS buffer
for FACS flow cytometry. Cell acquisition was performed on a
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA).
10,000 events were processed for each measurement. Data was
analyzed using FlowJo software (Tree Star Inc., Ashland, OR).
GLUCOSE UPTAKE ASSAY
Glucose uptake assay kits (Caymen Chem, Ann Harbor, MI)
were used to assess and quantify glucose uptake capacity
after fatty acid, endocannabinoid, or ECS receptor inhibitor
treatment. Glucose is taken up by the majority of cells via
the action of glucose transporters, which facilitate glucose
movement down a concentration gradient, in contrast to
energy-dependent uptake of glucose in the gut or kidney. Use of
a recently developed fluorescent glucose analog, 2-deoxy-2-[(7-
nitro-2,1,3-benzoxadiazol-4-yl) amino]-D-glucose) (2-NBDG),
allows for the target investigation of glucose uptake without
having to account for glucose metabolism or conversion to glyco-
gen once taken up by cells. 2-NBDG is a fluorescently-labeled
deoxyglucose analog and is used as the sole probe for detection.
Proliferating and differentiating C2C12 cells were seeded
at ∼5 ×104 cells/well in black walled/clear bottom 96-well plates
(Corning, Inc., Corning, NY, USA) in DMEM (+1% Pen/Strep
and 10% FBS). Upon reaching a confluency of 50%, differenti-
ation was induced with differentiating media consisting of high
glucose DMEM, 2% Horse Serum (HS), and 1% Pen/Strep. After
48 h,media was changed to specific PUFA or EC containingmedia
at a concentration of 5, 10, or 25μM or cannabinoid receptor
inhibitor (1, 2, or 5μM) for 24 h. Following PUFA enrichment,
media was removed from wells and treated with 100μg/mL
2-NBDG for 1 h. Afterwards plates were centrifuged for 5min at
500 g at room temperature and washed twice with the provided
cell-based assay. 2-NBDG taken up by the cells was thenmeasured
at a wavelength of 485/535 nm (excitation/emission) on a BioTek
Synergy HT plate reader (BioTek Instruments, Inc., Winooski,
VT, USA).
STATISTICAL ANALYSES
The results from experiments on gene expression and glucose
uptake in proliferating and differentiated C2C12 cell cultures
were analyzed for significance by One-Way ANOVA at P < 0.05.
Where significant differences were found, a Tukey’s Multiple
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Comparison Test was performed at a probability of α = 0.05 (SAS
for Windows version 9.3, SAS Institute Inc., Cary, NC). The data
are presented asmeans± s.e.m. as well asmeans± SDwhere indi-
cated with n = 3 for each treatment group. These data were also
expressed as standardized differences calculated from the differ-
ence between values of treatment and control divided by themean
of the control replicates [(treatment—BSA)/BSA ∗ 100, BSA is the
mean of 3 BSAs]. The results from experiments on CB1 and CB2
receptor expression in proliferating and differentiated C2C12 cell
cultures were performed via FACS flow cytometry were analyzed
for significance by One-Way ANOVA at P < 0.05. Where signifi-
cant differences were found, a Tukey’s Multiple Comparison Test
was performed at a probability of α = 0.05. These data were also
expressed as standardized differences calculated from the differ-
ence between values of treatment and control divided by themean
of the control replicates [(treatment—BSA)/BSA ∗ 100, BSA is the
mean of 3 BSA values]. Flow cytometry data were also compared
among three concentrations for the same treatment by One-Way
ANOVA. A Two-Way ANOVA analysis was further performed on
flow cytometry data to detect any interactions between the vari-
ous treatments and the three tested concentrations of each treat-
ment. Results from the analysis of fatty acid methyl esters (FAME)
by gas chromatography to reflect the fatty acid composition of
enriched C2C12 cell cultures (proliferating and differentiated)
were analyzed by a One-Way ANOVA at P < 0.05. Where signifi-
cant differences were found, a Tukey’s Multiple Comparison Test
was performed at a probability of α = 0.05. The FAME data are
expressed as means± s.e.m. Each treatment group was comprised
of three replicates.
Results from experiments on glucose uptake assay were per-
formed in proliferating and differentiated C2C12 after PUFA
or EC and inhibitor treatments (expressed as relative units
of fluorescence). The collected data were analyzed for signifi-
cance by one-way ANOVA at P < 0.05. Where significant dif-
ferences were found, a Tukey’s Multiple Comparison Test was
performed at a probability of α = 0.05. These data are pre-
sented as means ± s.e.m. as well as means ± SD with n = 3 for
each treatment group. Glucose uptake data were also adjusted
by cell numbers expressed as relative units of fluorescence/5000
cells and same statistical procedures were applied to this set of
data. Glucose uptake data were further expressed as standard-
ized differences calculated from the difference between values of
treatment and control divided by the mean of the control repli-
cates [(treatment—BSA)/BSA ∗ 100, BSA is the mean of 3 BSAs].
The same statistical procedure was applied to the adjusted and
standardized data for the evaluation of results.
RESULTS
FATTY ACID ANALYSIS OF LIPIDS FROM C2C12 CELL CULTURES
C2C12 myoblasts were cultured for 24 h following subculturing
to allow cells to attach to flasks. Following 24 h, cells desig-
nated for differentiation were exposed to DM for 48 h, when
myotubes formation was present and levels of myogenin and
MyoD1 mRNA were elevated verified by RT-PCR. Both differ-
entiated and proliferating cells were treated with either 25μM
of AA, EPA, DHA, AEA, 2-AG, or the no-fatty acid vehicle con-
trol, BSA. The fatty acid composition of total lipids extracted
from differentiated C2C12 cells after enrichment is shown in
Table 2 and for proliferating cells supplemental Table S1. The
PUFA enrichment of cell cultures demonstrated a multiple fold
increase in the respective PUFA enrichment and n-3 PUFA
decreased the levels of AA. Likewise AA treatment resulted in
lower levels of EPA and DHA in myoblast cultures. Treatment
of cultures with AEA resulted in lower 18:2n6 but higher 20:1n9
in differentiated cells compared to the BSA vehicle control cell
cultures. 2-AG treatment of differentiated myoblast cultures
resulted in lower t16:1, 16:1n7, 18:1n9, 18:1n7, 18:2n6, and
20:5n3 and higher 20:1n9, 20:4n6, 22:4n6, and 22:5n3 (Table 2).
Proliferating C2C12 cell cultures treated with 2-AG had lower
t16:1, 16:1n7, 18:1n9, 18:1n7, and 18:2n6 and higher 20:4n6,
22:4n6 (Table S1).
DHA TREATMENT LEADS TO A COMPENSATORY EXPRESSION OF
ECS-RELATED GENES SUGGESTING A DAMPENING OF ECS
ACTIVATION
Analysis of mRNA by quantitative RT-PCR from proliferating and
differentiated C2C12 myoblasts that were treated with 25μM of
either AA, EPA, DHA, AEA, 2-AG or a no-fatty acid BSA vehicle
control revealed several changes on ECS- and glucose uptake -
related mRNA expression when normalized to the housekeeping
gene GAPDH. These data were pooled for analysis from two sepa-
rate experiments (Table 3 differentiated cell cultures and Table S2
proliferating cell cultures).
Cannabinoid receptors CB1 and CB2
Compared to the BSA vehicle control cell cultures a higher expres-
sion of both CB1 and CB2 was observed with DHA, EPA, DHA,
EPEA, and DHEA treatment of differentiated cells (Table 3). A
lower expression of CB1 and CB2 was observed with AA, AEA,
and 2-AG treatment of differentiated cell cultures. Treatment with
AA, DHA, EPA, EPEA, and DHEA resulted in a higher amount of
mRNA for CB1 and CB2 in proliferating myoblasts (Table S2). In
these experiments n-3 PUFA and EPEA and DHEA resulted in the
highest amount of cannabinoid receptor mRNA.
Synthesis and degradation enzymes
The treatment of differentiated C2C12 cell cultures with
AA or AEA resulted in lower mRNA expression of NAPE-
PLD while higher expression occurred with EPA treatment
(Table 3). Expression of the synthesizing enzymes for 2-
AG, DAGLα and DAGLβ, were also measured. DAGLα
and DAGLβ were both observed to have higher expression
with AA or EPA enrichment while 2-AG had an oppo-
site effect and lowered mRNA expression of both enzymes.
The enzyme responsible for degradation of AEA and 2-AG
through hydrolysis is FAAH. This enzyme was found to be
higher with AA, EPA, and AEA treatment of C2C12 cell
cultures.
Similar to the differentiated cells, proliferating C2C12 cell
cultures treated with AA or AEA, NAPE-PLD, which is the synthe-
sizing enzyme for AEA, was lower compared to the no-fatty acid
BSA vehicle control (Table S2). A higher expression of NAPE-
PLD mRNA was observed with EPA and DHA treatment. AA,
DHA, and AEA resulted in a higher expression of DAGLα, while
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Table 2 | Fatty acid composition of total lipids from differentiated C2C12 cell cultures.
Fatty acid Treatments Pooled s.e.m ANOVA p value
BSA AA EPA DHA AEA 2-AG
14:0 1.07a 0.68b 0.65b 0.71b 1.02a 1.05a 0.05 <0.0001
14:1n5
15:0
16:0 13.70a 11.39c 11.97b 12.21b 13.42a 13.32a 0.10 <0.0001
t16:1 2.31a 1.42d 1.49d 1.74c 2.29a 2.09b 0.03 <0.0001
16:1n7 4.64a 2.49d 2.70cd 2.88c 4.65a 3.81b 0.05 <0.0001
17:0 0b 0b 0.37a 0.18ab 0.08b 0.07b 0.06 0.0066
18:0 13.74ab 12.44b 13.56ab 13.05ab 14.15a 14.05a 0.31 0.018
18:1n9 19.80a 11.67e 12.90d 13.95c 19.69a 16.50b 0.15 <0.0001
18:1n7 7.04a 4.91d 5.06cd 5.27c 7.12a 6.32b 0.05 <0.0001
18:2n6 4.28a 2.11e 3.49d 3.70c 4.01b 3.52d 0.03 <0.0001
18:3n6 0.11b 0.70a 0.29b 0b 0.19b 0.16b 0.07 0.0002
18:3n3
20:0
20:1n9 0b 0b 0b 0b 0.32a 0.19a 0.04 0.0002
20:2n6
20:3n6 1.79a 0.28c 1.04b 1.34ab 1.68a 1.39ab 0.12 <0.0001
20:4n6 9.31c 33.94a 6.37e 7.06d 9.20c 15.58b 0.18 <0.0001
20:3n3
20:5n3 1.87c 0.69e 21.57a 4.41b 1.75c 1.66d 0.22 <0.0001
22:0 0 0 0.08 0 0 0 0.03 0.46
22:1n9
22:4n6 0.83c 4.09a 0.67d 0.48e 0.84c 1.22b 0.01 <0.0001
22:5n6
22:5n3 3.17c 2.45d 7.03a 1.94e 3.18c 3.40b 0.04 <0.0001
22:6n3 3.68b 2.23c 2.29c 22.09a 3.84b 3.73b 0.06 <0.0001
24:0 0.10 0 0 0 0.08 0.17 0.06 0.35
24:1n9 0.22 0 0.10 0.13 0.20 0.21 0.10 0.61
Saturated 28.61ab 24.51d 26.62bc 26.15cd 28.75a 28.67ab 0.43 <0.0001
Monounsaturated 31.70a 19.08e 20.76d 22.23c 31.98a 27.03b 0.18 <0.0001
Total PUFA 25.04d 46.49a 42.76b 41.01b 24.69d 30.65c 0.42 <0.0001
n-6 PUFA 16.32c 41.11a 11.87d 12.58d 15.92c 21.87b 0.19 <0.0001
n-3 PUFA 8.72c 5.37d 30.89a 28.44b 8.77c 8.79c 0.28 <0.0001
Ratio of n-6/n-3 1.87c 7.65a 0.38d 0.44d 1.81c 2.49b 0.01 <0.0001
Data represent means of n = 3 for each group and the pooled s.e.m. Values within rows having different superscripts are significantly different by One-way ANOVA
and Tukey’s mean separation test at α = 0.05. BSA, bovine serum albumin; AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; AEA,
anandamide; 2AG, 2-arachidonoyl glycerol
AA, EPA, and AEA led to a higher DAGLβ expression. FAAH
was observed here to be lower with AEA and AA treatment of
proliferating C2C12 cell cultures.
ECS Confirmation (MAPK+ Adenylyl cyclase)
In order to determine potential ECS receptor activity, several
downstream events known to occur with activation were ana-
lyzed (Felder et al., 1993; Rolli-Derkinderen et al., 2003; Howlett,
2005). Here we see a lower expression of adenylyl cyclase and
a higher expression of the MAPK enzymes, p42/p44, p38, and
Jun N-terminal kinase (JNK) with only AEA and 2-AG in
both proliferating and differentiated myoblasts (Tables 3, S2),
which is consistent with the literature in confirming activation
of the cannabinoid receptors (Felder et al., 1993; Howlett,
2005).
Glucose aspects
In proliferating C2C12 cultures, AA led to lower mRNA
expression of insulin-R, GLUT1, and IRS-1. Contrastingly,
DHA was found to have higher insulin-R, GLUT4, GLUT1,
and IRS-1 mRNA expression. EPA was observed to have
no significant changes to any of the genes involved in
glucose uptake. AEA was observed to lower the mRNA
expression of Akt-1, insulin-R, GLUT4, GLUT1, and
IRS-1. 2-AG was also observed to have a negative effect
on these glucose-related genes as Akt-1, GLUT1, and
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Table 3 | mRNA expression in differentiated C2C12 myoblast cultures treated with PUFA and EC.
Measurement BSA AA DHA EPA AEA 2-AG EPEA DHEA Pooled s.e.m. ANOVA p value
CB1 1.0e 0.7f 2.1b 1.5d 0.8f 0.8f 1.8c 2.3a 0.02 <0.0001
CB2 1.0d 0.6e 2.3a 1.5c 0.7e 0.8de 1.8b 0.8de 0.1 <0.0001
NAPE-PLD 1.0c 0.7e 0.8de 1.6a 0.5f 0.9cd 1.7a 1.2b 0.03 <0.0001
FAAH 1.0d 1.5c 0.9d 2.8a 2.4b 1.1d 1.6c 1.5c 0.1 <0.0001
DAGL-α 1.0c 2.4b 0.9cd 3.4a 1.0c 0.7d 1.1c 1.0c 0.0 <0.0001
DAGL-β 1.0cd 2.1b 0.8de 3.4a 1.1c 0.6e 1.1c 1.1cd 0.1 <0.0001
Akt-1 1.0de 0.9ef 1.7b 1.3c 0.8f 1.0d 1.0de 2.6a 0.03 <0.0001
Insulin r 1.0c 0.8d 1.7b 1.1c 0.7d 0.8d 1.1c 2.4a 0.04 <0.0001
IRS-1 1.0c 0.8d 1.5b 1.1c 0.1e 0.1e 1.1c 1.7a 0.02 <0.0001
GLUT4 1.0bc 0.9cd 3.1a 1.0bc 0.8d 0.8d 1.1b 3.3a 0.05 <0.0001
GLUT1 1.0c 0.7d 1.5b 1.1c 0.2e 0.3e 1.1c 3.8a 0.02 <0.0001
Myogenin 1.0b 1.2b 1.6a 1.1b 1.1b 1.1b 1.1b 1.0b 0.04 <0.0001
MyoD1 1.0b 1.2b 1.5a 1.2b 1.2b 1.1b 1.0b 1.0b 0.04 <0.0001
IL-6 1.0c 1.5b 0.5d 1.1c 1.9a 1.6b 0.6d 0.5d 0.02 <0.0001
TNF-α 1.0a 0.7bc 0.7b 1.0a 0.6cd 0.5cd 1.0a 0.5d 0.03 <0.0001
AMPK α2 1.0d 1.0d 1.6b 1.1d 0.7e 0.7e 1.3c 1.8a 0.02 <0.0001
Adenylyl Cyclase 1.0a 1.0a 1.0a 1.0a 0.3d 0.2d 0.8b 0.6c 0.02 <0.0001
p42/p44 (MAPK) 1.0e 1.4d 0.8f 0.7f 1.7c 1.6c 1.9b 2.9a 0.03 <0.0001
p38 (MAPK) 1.0cd 1.2bcd 0.8d 0.9d 1.5bc 1.3bcd 1.6b 3.8a 0.12 <0.0001
JNK (MAPK) 1.0e 1.1d 0.8f 0.9ef 1.4c 1.3cd 1.9b 3.5a 0.03 <0.0001
STANDARD DEVIATION
CB1 0.01 0.1 0.00001 0.04 0.01 0.1 0.02 0.1
CB2 0.03 0.01 0.2 0.2 0.02 0.02 0.02 0.02
NAPE-PLD 0.03 0.03 0.03 0.04 0.05 0.1 0.1 0.03
FAAH 0.03 0.1 0.1 0.1 0.2 0.04 0.02 0.1
DAGL-α 0.04 0.1 0.1 0.2 0.1 0.05 0.1 0.03
DAGL-β 0.1 0.1 0.1 0.2 0.04 0.04 0.1 0.1
Akt-1 0.1 0.001 0.02 0.1 0.04 0.04 0.04 0.1
Insulin r 0.1 0.03 0.1 0.1 0.02 0.03 0.03 0.1
GLUT4 0.05 0.1 0.04 0.2 0.04 0.03 0.01 0.1
Myogenin 0.1 0.04 0.1 0.1 0.002 0.1 0.001 0.03
MyoD1 0.04 0.1 0.1 0.1 0.1 0.05 0.05 0.03
GLUT1 0.02 0.01 0.02 0.1 0.01 0.01 0.1 0.1
IRS-1 0.02 0.01 0.04 0.1 0.001 0.001 0.03 0.05
IL-6 0.03 0.1 0.01 0.1 0.02 0.1 0.01 0.01
TNF-α 0.1 0.01 0.03 0.1 0.01 0.02 0.04 0.01
AMPK α2 0.02 0.02 0.05 0.1 0.1 0.03 0.03 0.03
Adenylyl Cyclase 0.02 0.03 0.1 0.1 0.01 0.01 0.04 0.02
p42/p44 (MAPK) 0.04 0.04 0.03 0.03 0.02 0.1 0.1 0.1
p38 (MAPK) 0.02 0.02 0.02 0.1 0.0005 0.05 0.4 0.4
JNK (MAPK) 0.01 0.04 0.02 0.1 0.04 0.02 0.04 0.1
Data in the upper section of the table represent means of n = 3 for each cell culture group. qPCR output expressed in Ct normalized to BSA control. Values
within rows having different superscripts are significantly different by One-Way ANOVA and Tukey’s mean separation test at α = 0.05. Values in the lower section of
the table are the standard deviations of all means.
BSA, bovine serum albumin; AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; AEA, anandamide; 2AG, 2-arachidonoyl glycerol; CB1,
cannabinoid receptor 1; CB2, cannabinoid receptor 2; NAPE-PLD, N-acyl phosphatidylethanolamine phospholipase D; FAAH, fatty acid amide hydrolase; DAGLα,
diacylglycerol lipase-α; DAGLβ, diacylglycerol lipase-β; Akt1, RAC-alpha serine/threonine-protein kinase (protein kinase B); INS-R, insulin receptor; GLUT4, glucose
transporter type 4; MyoD1, myogenic differentiation interleukin-6, IL-6; tumor necrosis factor-α, TNF-α.
IRS-1 were all lower compared to the no-fatty acid vehicle
control.
Many of the observations found in the proliferating cells were
found to be the same in the differentiated C2C12 myoblasts. AA
was found to lower the expression of Akt-1, insulin-R, GLUT1,
and IRS-1. Again, DHA resulted in higher mRNA expression of
Akt-1, insulin-R, GLUT4, GLUT1, and IRS-1. EPA led to higher
Akt-1 expression. AEA resulted in lower Akt-1, insulin-R, GLUT4,
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GLUT1, and IRS-1 expression while 2-AG had a lowering effect
on insulin-R, GLUT4, GLUT1, and IRS-1 mRNA.
Inflammation
In proliferating C2C12 myoblasts, inflammatory cytokine mRNA
expression were analyzed and showed a higher IL-6 and TNF-α
with AA, AEA, and 2-AG treatments while DHA enrichment led
to a lower expression of the two inflammatory maker mRNA. In
differentiated C2C12 myoblasts, IL-6 expression was shown to be
lower by DHA enrichment and higher after AA, AEA, and 2-AG
treatment. TNF-α expression was found to be lower with AA,
DHA, AEA, and 2-AG treatment while EPA enrichment had no
effect.
PUFA AND EC TREATMENT RESULTED IN VARYING CB1 AND CB2
EXPRESSION
Western blot analysis followed by densitometry was performed
to measure CB1 and CB2 expression in differentiated and
proliferating C2C12 myoblasts after being treated with either
25μM of AA, EPA, DHA, AEA, 2-AG or a no-fatty acid vehi-
cle control (Figure 1). In differentiated C2C12 myoblasts, AA,
EPA, and DHA resulted in higher protein expression of CB1 com-
pared to the BSA control group. CB2 protein expression was
higher for AA, EPA, DHA, AEA, and 2-AG treated differentiated
C2C12 myoblasts. Compared to the BSA vehicle control, EPA and
DHA enrichment showed higher expression of CB1 and CB2 in
proliferating C2C12 myoblasts while AEA treatment had lower
expression.
FACS-flow cytometry was performed tomeasure CB1 and CB2
expression in differentiated and proliferating C2C12 myoblasts
after being treated with either 25μM of AA, EPA, DHA, AEA,
2-AG or a no-fatty acid vehicle control (Figure 2). A One-Way
ANOVA revealed in differentiated C2C12 myoblasts, that DHA
enrichment resulted in a higher expression of CB1 while AEA
and 2-AG lower CB1 expression. CB2 expression was higher with
DHA alone, while a lower amount was found with AA, AEA,
and 2-AG treatment. A significant decrease in both CB1 and CB2
expression was observed with AA, EPA, DHA, AEA, or 2-AG
treatment compared to the BSA control in proliferating cells.
GLUCOSE UPTAKE IS ENHANCED WITH DHEA TREATMENT
Non-insulin stimulated glucose uptake was assessed in differen-
tiated and proliferating C2C12 myoblasts after treatment with
either 25μM of AA, EPA, DHA, AEA, 2-AG, or 1μM NESS0327
(CB1 inhibitor), 1μM AM630 (CB2 inhibitor) or a BSA no-fatty
acid vehicle control (Figure 3). In both differentiated and prolif-
erating C2C12 cell cultures, AEA and 2-AG were found to result
in lower glucose uptake compared to the BSA vehicle control cell
cultures. However, EPEA, DHEA, NESS0327, and AM630 treat-
ments showed higher glucose uptake. The results are presented as
means ± SD in Table S3.
DISCUSSION
Enrichment of proliferating and differentiated C2C12 myoblasts
with AA resulted in an increase in n-6 PUFA and the ratio of
n-6/n-3 with a decrease in n-3 PUFA. Conversely, EPA or DHA
treatment resulted in the opposite effect of the AA enrichment
as an increase in n-3 PUFA with a decrease in n-6 PUFA was
FIGURE 1 | Western blot analysis of CB1 and CB2 expression in
proliferating and differentiated C2C12 myoblast cultures treated with
PUFA and EC. C2C12 cultures were treated with 25μM of respective
treatments for 24 h. The bars are the means ± SD (error bars) of 2
experiments performed in triplicate. The asterisk (∗) signifies difference
compared to the BSA control for CB1 while the plus sign (+) indicates
difference compared to the BSA control for CB2. In proliferating cells
compared to the BSA vehicle control, DHA and EPA values for both
receptors were higher; CB1 was lower in the AEA treatment. In
differentiating cells compared to the BSA vehicle control, all treatments
showed higher CB2 protein expression but only AA, DHA and EPA
treatments were higher for CB1.
observed, resulting in a lower ratio of n-6/n-3 PUFA. These
results are in accordance with previous findings in muscle and
bone compartments of rodents fed n-6 or n-3 PUFA enriched
diets (Watkins et al., 2000; Li et al., 2003; Watkins et al., 2006;
Hutchins-Wiese et al., 2012). An aspect that differed from other
fatty acid enrichment studies is the exclusion of FBS in enrich-
ing media. This exclusion allows for greater control of availing
specific fatty acid exposure to cultures.
Our findings are the first to demonstrate that differenti-
ated and proliferating C2C12 myoblasts cell cultures express key
ECS-related components. Furthermore, the ECS-related compo-
nents can be altered with PUFA or endocannabinoid exposure.
An interesting finding was the observed increase in AA with 2-AG
enrichment in both differentiated and proliferating cells. While
this observation is the first to report this finding, it is very likely
a result of 2-AG hydrolysis leading to the liberation and elevation
of AA in cell lipids.
Several recent studies have demonstrated that endocannabi-
noid concentrations in tissues and in circulation are responsive
to the types of dietary n-6 and n-3 PUFA when fed to animals or
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FIGURE 2 | FACS flow cytometry analysis of CB1 and CB2 expression
in proliferating and differentiated C2C12 myoblast cultures treated
with PUFA and EC. C2C12 cultures were treated with 25μM
concentrations of respective treatments for 24 h. The bars are the means ±
SD (error bars) of 3 experiments performed in triplicate. The asterisk (∗)
signifies difference compared to the BSA control for CB1 while the plus
sign (+) indicates difference compared to the BSA control for CB2. In
proliferating cells all treatments were different compared to the BSA vehicle
control. In differentiating cells compared to the BSA vehicle control, DHA
had higher CB1 and CB2 values and AEA and 2-AG were lower values but
CB2 was lower in the AA cells.
in cell cultures. Studies with mouse adipocytes incubated with AA
or DHA (100μM) for 72 h showed elevated levels of these PUFA
in phospholipids (Matias et al., 2008). AA treatment in these
cells led to an increase in 2-AG concentrations. Moreover, DHA
treatment significantly decreased both AEA and 2-AG concen-
trations compared to the control. This study demonstrated that
fatty acid enrichment of adipocytes in culture could also modify
endocannabinoid concentrations with specificity. Several studies
showed that dietary PUFA altered the levels of endocannabinoids
in tissues including brain (Watanabe et al., 2003) adipose (Batetta
et al., 2009), and liver (Artmann et al., 2008; Batetta et al., 2009).
Aside from the ligands of the ECS, our laboratory (Hutchins et al.,
2011) reported that EPA enrichment reduced the mRNA levels
for the AEA synthesizing enzyme, NAPE-PLD, compared to AA
and the vehicle control groups in MC3T3-E1 osteoblast-like cell
cultures. While it isn’t clear whether PUFA directly affect the
cannabinoid receptors, CB2 mRNA was also reduced with EPA
treatment. If and how long chain n-3 PUFA affect different cell
types in a similar fashion, that is by impacting the ECS recep-
tor expression, in culture or at different stages (differentiated or
proliferating) and if similar responses occur in vivo, has not been
investigated.
Our findings provide new evidence that the C2C12 myoblast
cell line expresses ECS receptors and both synthesis and degra-
dation enzymes. Further we report that treatment with PUFA
or endocannabinoids were able to influence ECS tone and ulti-
mately, signaling potential of the ECS in these cells. It is evident
from the data presented here that with 24 h n-3 PUFA treatment,
either EPA or DHA, the ECS tone is potentially upregulated. The
mRNA and Western blot analysis for both CB1 and CB2 expres-
sion in proliferating and differentiated myoblast cultures were
found to be higher than in the BSA vehicle control cell cultures.
These findings are illustrated in Figure 4. The cannabinoid recep-
tors were also found to be higher in differentiated cultures when
analyzed by flow cytometry. Both EPA and DHA enrichment also
resulted in higher endocannabinoid synthesis enzymes, NAPE-
PLD and DAGLα/β, in proliferating while only EPA demonstrated
the effect in differentiated C2C12 cell cultures.
Identification of components of the ECS in our cell system val-
idates the model and was consistent with the literature, in which
CB1 and CB2 was found in human skeletal muscle (Cavuoto
et al., 2007; Eckardt et al., 2009) and differentiated L6 myotubes
(Esposito et al., 2008). While the majority of ECS studies in mus-
cle have focused on pharmacological interventions to monitor
energy expenditure (Liu et al., 2005), mainly dealing with the
short-lived antiobesity drug, Rimonabant (SR141716) (Esposito
et al., 2008; Eckardt et al., 2009), the current investigation is the
first to interrogate the ECS in muscle cells using dietary PUFA.
In proliferating C2C12 treated with AA, a decrease of NAPE-
PLD was observed, the enzyme for AEA biosynthesis. It is pos-
sible that because of the abundant availability of the PUFA
precursor, the synthesizing enzyme is being maximally satu-
rated and less synthesis of AEA is required by the cell, result-
ing in a downregulation at the mRNA level of the enzyme.
This is supported by the results with DHA and EPA treat-
ments and both are potential precursors of endocannabinoids,
DHEA and EPEA, respectively that were found to result in
higher NAPE-PLD mRNA compared to the BSA control cells.
The n-3 PUFA ethanolamides, docosahexaenoyl ethanolamide
(DHEA) and eicosapentaenoyl ethanolamide (EPEA), have been
previously shown to be weak ligands to cannabinoid receptors
when compared to AEA (Sheskin et al., 1997), suggesting that
the upregulation of ECS-related synthesis enzymes observed in
this study are attributed to a compensatory response. Structure
activity relationships suggest that the n-pentyl chain in AEA is
necessary for optimal binding to the CB1 receptor (Felder et al.,
1993); however, data relating to CB2 is inadequate. In addition,
DHEA also binds to other receptors including PPARs (Artmann
et al., 2008), highlighting the complexity of NAE signaling. Even
with lower affinity to the cannabinoid receptors, perhaps the
n-3 PUFA-derived ethanolamides are synthesized at a greater
propensity leading to an inflated competition with other endo-
cannabinoids resulting in the higher CB1 and CB2 expression
seen in this study.
To confirm expression of activation of the ECS by AEA
and 2-AG, the signaling pathway leading to the sequential acti-
vation of mitogen-activated protein kinase (MAPK) were also
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FIGURE 3 | Glucose uptake analysis of proliferating and differentiated
C2C12 myoblast cultures treated with either three concentrations (5,
10, or 25μM) of PUFA (AA, EPA, or DHA) or endocannabinoid (AEA,
2-AG, EPEA or DHEA) or with three concentrations (1, 2, or 5μM) of
cannabinoid receptor antagonist (AM630 or NESS0327) for 24h.
Values shown are means of 3 experiments performed in triplicate. In
proliferating cells compared to the BSA vehicle control (gray shaded
line), DHA, DHEA, EPEA, AM630, and NESS0327 had higher glucose
uptake while AA, AEA, and 2-AG had lower glucose uptake. In
differentiated cells compared to the BSA vehicle control, glucose uptake
was lower for AEA and 2-AG treatments while all other treatments were
higher. Data were analyzed by a One-Way ANOVA and Tukey’s mean
separation test at α = 0.05.The mean values and pooled s.e.m are shown
in the supplemental materials Table S3.
investigated here. Stimulation of either CB1 or CB2 has previ-
ously been shown to lead to the phosphorylation and activation
of p42/p44 MAPK, p38 MAPK, and Jun N-terminal kinase (JNK)
(Rolli-Derkinderen et al., 2003; Howlett, 2005; Eckardt et al.,
2009). The endocannabinoids AEA, 2-AG, EPEA, and DHEA
were all shown to increase the mRNA expression of these signal-
ing pathways markers that regulate nuclear transcription factors.
Additionally, a lowered expression of adenylyl cyclase mRNA
with the endocannabinoid treatments was observed, concurring
with observations of cannabinoid receptor activation (Felder
et al., 1993; Howlett, 2005). Conversely, EPA and DHA showed a
decrease in mRNA expression in p42/p44 MAPK, p38MAPK, and
JNK in differentiated C2C12 with proliferating cells only being
affected by DHA enrichment. Previously, it has been reported
that fish oil decreased these MAPK-family signaling molecules
(Lo et al., 2000). From the mRNA analysis, DHEA and EPEA
had the highest fold change in p38 MAPK. p38 MAPK has been
found to be lower in the liver of obese and type II diabetic mice
(Lee et al., 2011). Activation of p38 MAPK was found to reduce
endoplasmic reticulum stress and establish euglycemia in these
severely obese mice. The MAPK/ERK signaling pathway has also
been found to regulate insulin sensitivity into moderate glucose
metabolism in Drosophila (Zhang et al., 2011). Further investi-
gations of the ECS should focus on this pathway to ascertain the
potential of restoring proper glucose homeostasis in obese and
type II diabetics.
Signal transduction pathways involving MAPKs as well as
the phosphatidylinositol 3-kinase (PI3-K) have been previously
found to be key signaling cascades involved in the differentia-
tion process of myoblasts (Zetser et al., 1999; Li and Johnson,
2006). However, the results of studies on the role of MAPKs in
regulating skeletal muscle differentiation have been controver-
sial. For example, activation of the ERK pathway seems to be
important for mediating the repressive effect of growth factors
on myogenesis. One study has suggested that ERK activation pos-
itively regulates myogenesis (Weyman and Wolfman, 1998). JNK
has been involved in controlling diverse cellular functions, includ-
ing cell proliferation, differentiation, and apoptosis (Garrington
and Johnson, 1999). The activity of JNK has been reported to
be activated during differentiation of C2 myoblasts and essen-
tial for survival (Bennett and Tonks, 1997; Khurana and Dey,
2004). Additionally, the role of MAPKs in the proliferation of
skeletal muscle has not yet been fully studied, although inhibi-
tion of their activation is known to lead growth arrest in many
cells, including myoblasts. Lipina et al. (2010) has also examined
the effects of targeting CB1 and its downstream effects, finding
that impeding CB1 activation enhanced both insulin-stimulated
ERK1/2 and PI3-K/protein kinase-B activity in L6 myotubes. To
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FIGURE 4 | The illustration summarizes the actions of PUFA,
endocannabinoids, and cannabinoid antagonist and inverse agonist
on glucose uptake and ECS gene expression in differentiated C2C12
myoblast cell cultures. Differentiated C2C12 cultures treated with AA and
its derived ligands, AEA and 2-AG, led to lower basal glucose uptake
compared to the BSA vehicle control group. Treatment with DHA, DHEA,
EPA, and EPEA resulted in higher basal glucose uptake compared to the
BSA control group. The higher levels of glucose uptake were comparable to
the uptake observed with the CB1 antagonist, NESS0327. The figure is
developed from the key observations found by treatment of C2C12
myoblast cell cultures with PUFA, endocannabinoids, and cannabinoid
receptor antagonism on CB1, inverse agonist on CB2, and the
measurement of GLUT1, insulin-R mRNA, and glucose uptake in
differentiated C2C12. In the table below upward arrows represent higher
expression/activity compared to the BSA vehicle control while downward
arrows signify lower expression/activity compared to the BSA control.
Differentiated C2C12 cultures treated with AA and its derived ligands, AEA
and 2-AG, led to lower CB1, GLUT1, and insulin-R mRNA expression as well
as a reduction of basal glucose uptake compared to the BSA control group.
Treatment with DHA, DHEA, EPA, and EPEA resulted in higher CB1, and
DHA or DHEA higher GLUT1 and insulin-R mRNA expression as well as a
greater level of glucose uptake compared to the BSA control group. NS
indicates not significant from the BSA control group.
add to these findings of insulin-sensitization in skeletal muscle
cells, our study demonstrates that antagonizing CB1 resulted in
increasing non-insulin stimulated glucose uptake.
The expression of the transcription factor myogenin is essen-
tial for the development of functional skeletal muscle as it is
required for the proper fusion of myogenic precursor cells during
myogenesis (Braun et al., 1989; Wright et al., 1989) Myogenin-
deficient myoblasts, however, are unable to undergo efficient
fusion to form functional muscle fibers in vivo. This result sug-
gests that myogenin plays an essential role in the differentiation
of myoblasts into myotubes (Hasty et al., 1993; Nabeshima et al.,
1993). Similarly, MyoD1 is one of the earliest markers of myo-
genic commitment from the mesoderm and is expressed in acti-
vated satellite cells (Edmondson and Olson, 1989). Myogenin
and MyoD1 have been shown to be expressed in regenerating
skeletal muscle of mice (Fuchtbauer and Westphal, 1992). While
there were no differences between treatments in the proliferating
C2C12, DHA enrichment led to a higher expression of myogenin
and MyoD1 in the differentiated cultures. Other findings in the
literature suggest that DHA increases proliferation in C2C12 cells
(Lee et al., 2009). However, the mechanism behind the ability of
DHA to modulate skeletal muscle differentiation, whether it is via
MAPK phosphorylation, has yet to be explained.
Some have reported that endocannabinoids are involved in the
hypothalamic regulation of food intake and in peripheral lipo-
genesis in rodents (Di Marzo et al., 2001; Osei-Hyiaman et al.,
2005). Thus the ECS has become a promising target for a pharma-
cological approach to obesity and diabetes. Antagonism of CB1
in rodents (Liu et al., 2005), primary myoblasts (Eckardt et al.,
2009), and L6 myoblasts (Esposito et al., 2008) using Rimonabant
(SR141716) have demonstrated effects on energy expenditure,
targeting improved glucosemetabolism, however, no information
is available, thus far, in directing this endogenous machinery by
dietary means, specifically with PUFA.
The key findings for glucose uptake in myoblasts are summa-
rized in Figure 4. Enrichment of proliferating C2C12 myoblasts
with EPA and DHA N-acylethanolamides, EPEA and DHEA,
respectively, NESS0327, and AM630 resulted in higher basal glu-
cose uptake in proliferating C2C12 cultures compared to the
BSA control. In differentiated myoblasts, AA, EPA, DHA, EPEA,
DHEA, NESS0327, and AM630 were all found to have higher
basal glucose uptake compared to the control cultures (Figure 4).
AEA and 2-AG both showed lower basal glucose uptake in both
proliferating and differentiated C2C12 (Figure 4), which is con-
sistent with the findings of elevated AEA and 2-AG in type II
diabetic patients (Engeli et al., 2005; Bluher et al., 2006; Matias
et al., 2006). Because of the elevated levels of endocannabinoids
found in obese animals (Di Marzo et al., 2001) and diabetic
humans (Engeli et al., 2005), activation of CB1 may be aug-
mented resulting in an interference with glucose metabolism
in muscle cells leading to a downregulation of glucose uptake.
Several studies have demonstrated that skeletal muscle is respon-
sive to ECS manipulation in mice (Liu et al., 2005). In a study
in leptin deficient obese mice, treatment with the CB1 antagonist
SR141716 induced a significant increase in glucose uptake in iso-
lated soleus muscle after 7 days of treatment. In this study GLUT1
was thought to be a possible factor responsible for the response
with SR141716 of increased glucose uptake in mouse muscle.
In our study of C2C12 cultures the CB1 antagonist NESS0327
resulted in the greatest uptake of glucose, validating previous
findings of the negative effects of CB1 on basal glucose uptake
(Liu et al., 2005; Esposito et al., 2008; Eckardt et al., 2009). Higher
expression of insulin-R, IRS-1, and GLUT4 with DHA treat-
ment is in contrast to the lower glucose uptake with AEA and
2-AG. Our findings suggest that DHA and DHEA have a positive
role in improving insulin-stimulated glucose uptake in myoblasts
(Figure 4).
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Additionally, AMPK activation has previously been found
to improve glucose tolerance (Buhl et al., 2002). Long-term
administration of 5-aminoimidazole-4-carboxamide ribonucleo-
side, a drug that activates AMPK, to insulin-resistant Zucker rats
was shown to improve glucose tolerance and other reduce lipid
accumulation. An increase in GLUT4 translocation in skeletal
muscle is mainly responsible for the observed improved glucose
tolerance (Holmes et al., 1999). Additionally, AMPK is activated
during exercise at intensities >60% VO2max in human subjects
and rats (Fujii et al., 2000; Takekoshi et al., 2006). An interest-
ing and relevant finding in our study was that both DHA and
DHEA were the only treatments that resulted in higher GLUT4
mRNA levels. DHA has previously been shown to increase intesti-
nal glucose absorption (Gabler et al., 2009). Most recently, DHA
enrichment has been shown to interact with AMPK in C2C12
myoblasts to enhance uncoupling protein expression (Lee et al.,
2013). DHEA was shown in the current investigation to improve
basal glucose uptake. Whether DHEA is able to activate AMPK to
effect GLUT1 remains to be determined. In addition, the observed
increase in glucose-related mRNA suggests that DHEA may be a
potential target in improving glucose clearance by muscle. Based
on our findings future experiments must be conducted to inves-
tigate specific mechanisms on how PUFA affect signaling of the
ECS in muscle and glucose utilization.
Based on the data presented herein, EPA and DHA enrich-
ment of differentiated and proliferating C2C12 myoblasts led to
a decrease in downstream markers of cannabinoid receptor acti-
vation. Conversely, endocannabinoids were all shown to increase
downstream markers of cannabinoid receptor activation. While
AEA and 2-AG treatment caused a marked decrease in adenylyl
cyclase, indicating potential activation of the cannabinoid recep-
tors, DHEA and EPEA resulted in a significantly higher mRNA
expression, suggesting secondary messenger signaling to be mod-
erated. Further, DHEA demonstrated an increase in basal glucose
uptake at levels comparable to the CB1 antagonist, NESS0327 in
myoblasts. Thus the current investigation demonstrates that long
chain n-3 PUFA can mediate ECS gene expression and cellular
activity in proliferating and differentiated myoblast cultures.
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